Terms: = Ovarian cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Diagnosis
70 results:
1. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
2. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
3. A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Horvat N; Causa Andrieu P; Meier A; Ji X; Lakhman Y; Soslow R; Allison D; Gangai N; Rodriguez L; Kattan MW; Chi DS; Hricak H
Gynecol Oncol; 2023 Sep; 176():90-97. PubMed ID: 37478617
[TBL] [Abstract] [Full Text] [Related]
4. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
[TBL] [Abstract] [Full Text] [Related]
5. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract] [Full Text] [Related]
6. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
7. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
8. Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
Kaur A; Wang S; Kumar A
Gynecol Oncol; 2023 Mar; 170():266-272. PubMed ID: 36738485
[TBL] [Abstract] [Full Text] [Related]
9. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
10. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract] [Full Text] [Related]
11. Clinico-genomic Characterization of atm and HRD in Pancreas cancer: Application for Practice.
Park W; O'Connor CA; Bandlamudi C; Forman D; Chou JF; Umeda S; Reyngold M; Varghese AM; Keane F; Balogun F; Yu KH; Kelsen DP; Crane C; Capanu M; Iacobuzio-Donahue C; O'Reilly EM
Clin Cancer Res; 2022 Nov; 28(21):4782-4792. PubMed ID: 36040493
[TBL] [Abstract] [Full Text] [Related]
12. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a diagnosis of Epithelial Tubo-ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract] [Full Text] [Related]
13. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: atm, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract] [Full Text] [Related]
14. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract] [Full Text] [Related]
15. Association of Pathogenic Variants in Hereditary cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract] [Full Text] [Related]
16. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract] [Full Text] [Related]
17. atm immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract] [Full Text] [Related]
18. Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts.
Siegmund S; Sholl LM; Cornejo KM; Sangoi AR; Otis CN; Mehra R; Hirsch MS; Acosta AM
Mod Pathol; 2022 May; 35(5):697-704. PubMed ID: 34845303
[TBL] [Abstract] [Full Text] [Related]
19. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Germline Testing Results of Men With Prostate cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421
[TBL] [Abstract] [Full Text] [Related]
[Next]
